DK1902141T3 - ADAMTS 13-holdige sammensætninger med thrombolytisk virkning - Google Patents

ADAMTS 13-holdige sammensætninger med thrombolytisk virkning

Info

Publication number
DK1902141T3
DK1902141T3 DK06754405.6T DK06754405T DK1902141T3 DK 1902141 T3 DK1902141 T3 DK 1902141T3 DK 06754405 T DK06754405 T DK 06754405T DK 1902141 T3 DK1902141 T3 DK 1902141T3
Authority
DK
Denmark
Prior art keywords
thrombus
adamts
containing compositions
thrombolytic effect
adamts13
Prior art date
Application number
DK06754405.6T
Other languages
English (en)
Inventor
Denisa Wagner
Anil Kumar Chauhan
Friedrich Scheiflinger
Barbara Plaimauer
Original Assignee
Baxter Int
Baxter Healthcare Sa
Cbr Inst For Biomedical Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int, Baxter Healthcare Sa, Cbr Inst For Biomedical Res filed Critical Baxter Int
Application granted granted Critical
Publication of DK1902141T3 publication Critical patent/DK1902141T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
DK06754405.6T 2005-06-17 2006-06-16 ADAMTS 13-holdige sammensætninger med thrombolytisk virkning DK1902141T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US69192705P 2005-06-17 2005-06-17
US72932305P 2005-10-21 2005-10-21
US77126506P 2006-02-07 2006-02-07
PCT/EP2006/005800 WO2006133955A1 (en) 2005-06-17 2006-06-16 Adamts13-comprising compositions having thrombolytic activity

Publications (1)

Publication Number Publication Date
DK1902141T3 true DK1902141T3 (da) 2012-05-07

Family

ID=36956096

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06754405.6T DK1902141T3 (da) 2005-06-17 2006-06-16 ADAMTS 13-holdige sammensætninger med thrombolytisk virkning

Country Status (10)

Country Link
US (4) US20070015703A1 (da)
EP (1) EP1902141B1 (da)
AT (1) ATE544866T1 (da)
AU (1) AU2006257073B2 (da)
CA (1) CA2606351C (da)
DK (1) DK1902141T3 (da)
ES (1) ES2382104T3 (da)
HK (1) HK1118579A1 (da)
PL (1) PL1902141T3 (da)
WO (1) WO2006133955A1 (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083786B2 (en) 1997-04-03 2006-08-01 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
PL1902141T3 (pl) 2005-06-17 2012-12-31 Baxalta Inc Kompozycje o działaniu trombolitycznym zawierające ADAMTS13
FR2918375B1 (fr) * 2007-07-05 2009-10-16 Lab Francais Du Fractionnement Utilisation d'un support de chromatographie pour reduire la quantite d'adamts13 dans une solution derivee du plasma
EP2288377A1 (en) * 2008-05-12 2011-03-02 Immune Disease Institute Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
NZ609908A (en) * 2008-10-27 2014-07-25 Baxter Int Models of thrombotic thrombocytopenic purpura and methods of use thereof
US8415114B2 (en) * 2008-12-05 2013-04-09 Baxter International Inc. Methods of measuring ADAMTS13-mediated in vivo cleavage of von Willebrand factor and uses thereof
JP5411582B2 (ja) * 2009-06-02 2014-02-12 一般財団法人化学及血清療法研究所 Ａｄａｍｔｓ１３による細胞移植増強補助剤
US8945895B2 (en) 2009-07-31 2015-02-03 Baxter International Inc. Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof
US8580554B2 (en) 2009-07-31 2013-11-12 Baxter International Inc. Method of producing a polypeptide or virus of interest in a continuous cell culture
US8623352B2 (en) 2009-09-21 2014-01-07 Baxter International Inc. Stabilized liquid and lyophilized ADAMTS13 formulations
PT2488203T (pt) * 2009-10-16 2017-03-10 Univ Leicester Métodos para tratamento de coagulação intravascular disseminada através da inibição da activação do complemento dependente de masp-2
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
CA3076975C (en) 2011-04-08 2024-06-18 Omeros Corporation Methods for treating conditions associated with masp-2 dependent complement activation
AU2013203062C1 (en) * 2013-03-15 2018-06-28 Takeda Pharmaceutical Company Limited Subcutaneous administration of adamts13
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
CN107109411B (zh) 2014-10-03 2022-07-01 冷泉港实验室 核基因输出的定向增加
CN105991563B (zh) * 2015-02-05 2020-07-03 阿里巴巴集团控股有限公司 一种保护敏感数据安全的方法、装置及三方服务系统
WO2016186994A1 (en) * 2015-05-15 2016-11-24 Children's Medical Center Corporation Methods relating to the diagnosis and treatment of thrombotic microangiopathy
AU2016334804B2 (en) 2015-10-09 2022-03-31 University Of Southampton Modulation of gene expression and screening for deregulated protein expression
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
CN109312343B (zh) 2015-12-14 2022-09-27 冷泉港实验室 用于治疗常染色体显性精神发育迟滞5型和Dravet综合征的反义寡聚体
WO2017119498A1 (ja) 2016-01-08 2017-07-13 国立大学法人京都大学 Ａｄａｍｔｓ１３を主成分とする診断薬および医薬品
SG11201900853SA (en) * 2016-08-04 2019-02-27 Baxalta Inc Use of adamts13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome
SI3673080T1 (sl) 2017-08-25 2024-03-29 Stoke Therapeutics, Inc. Protismiselni oligomeri za zdravljenje bolezenskih stanj in bolezni
US12060558B2 (en) 2018-05-04 2024-08-13 Stoke Therapeutics, Inc. Methods and compositions for treatment of cholesteryl ester storage disease
WO2021067668A1 (en) * 2019-10-04 2021-04-08 The Children's Medical Center Corporation Adamts13 treatment to enhance graft survival
WO2021198781A2 (en) 2020-04-02 2021-10-07 Takeda Pharmaceutical Company Limited Adamts13 variant, compositions, and uses thereof
IL298063A (en) 2020-05-11 2023-01-01 Stoke Therapeutics Inc opa1 antisense oligomers for the treatment of conditions and diseases
US20230201319A1 (en) 2020-05-22 2023-06-29 Takeda Pharmaceutical Company Limited Adamts13 compositions and methods for treating and diagnosing complications of coronavirus disease
CA3201986A1 (en) * 2020-11-18 2022-05-27 Green Cross Corporation Adamts13 variant having increased escaping rate or activity against autoantibody
KR20240112755A (ko) * 2023-01-11 2024-07-19 주식회사 녹십자 혈전성 질환의 예방 또는 치료를 위한 신규한 액상 제형물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5082218A (da) * 1973-11-10 1975-07-03
US4791138A (en) * 1983-12-14 1988-12-13 The Upjohn Company Method for treating or preventing deep vein thrombosis using lipoxygenase inhibitors
AU782496B2 (en) * 1999-07-13 2005-08-04 Bolder Biotechnology, Inc. Immunoglobulin fusion proteins
US6926894B2 (en) * 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
JP2003284570A (ja) 2001-04-25 2003-10-07 Chemo Sero Therapeut Res Inst フォンビルブラント因子（ｖＷＦ）切断酵素
AU2002336367A1 (en) * 2001-08-16 2003-03-03 The Regents Of The University Of Michigan Adamts13 genes and proteins and variants, and uses thereof
US20030073115A1 (en) * 2002-09-16 2003-04-17 Shyam Ramakrishnan Regulation of human galanin receptor-like g protein coupled receptor
US7763430B2 (en) * 2003-04-22 2010-07-27 Baxter International Inc. Diagnostic assay for anti-von Willebrand Factor cleaving protease (ADAMTS13) antibodies
EP1568782A1 (de) * 2004-02-25 2005-08-31 Clemens Bockmeyer Diagnose und Therapie von ADAMTS-13 assoziierten Erkrankungen
PL1902141T3 (pl) 2005-06-17 2012-12-31 Baxalta Inc Kompozycje o działaniu trombolitycznym zawierające ADAMTS13

Also Published As

Publication number Publication date
US20220002703A1 (en) 2022-01-06
WO2006133955A1 (en) 2006-12-21
AU2006257073A1 (en) 2006-12-21
US11124787B2 (en) 2021-09-21
US20130136732A1 (en) 2013-05-30
EP1902141A1 (en) 2008-03-26
US20070015703A1 (en) 2007-01-18
EP1902141B1 (en) 2012-02-08
ES2382104T3 (es) 2012-06-05
US20190161746A1 (en) 2019-05-30
US10233436B2 (en) 2019-03-19
AU2006257073B2 (en) 2011-08-04
CA2606351A1 (en) 2006-12-21
ATE544866T1 (de) 2012-02-15
PL1902141T3 (pl) 2012-12-31
HK1118579A1 (en) 2009-02-13
CA2606351C (en) 2016-12-13
WO2006133955A8 (en) 2007-11-29

Similar Documents

Publication Publication Date Title
DK1902141T3 (da) ADAMTS 13-holdige sammensætninger med thrombolytisk virkning
ATE464303T1 (de) Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
MX2012004551A (es) Nuevas composiciones para prevenir y/o tratar trastornos de almacenamiento lisosomal.
RS54707B1 (en) TREATMENT OF CROWN LAKVINIMOD DISEASE
EA200870019A1 (ru) Лактамовые соединения и способы их применения
TW200604168A (en) Azaindoles useful as inhibitors of rock and other protein kinases
IN2012DN03824A (da)
WO2008133647A3 (en) Antagonists of pcsk9
TW200602048A (en) Diphenylimidazopyrimidine and -imidazole amines as inhibitors of β -secretase
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
TW200745124A (en) Azepinoindole derivatives as pharmaceutical agents
MY155961A (en) Chemical compounds 251
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
MX2009009491A (es) Compuestos y composiciones como moduladores de la actividad del gpr119.
WO2010006219A3 (en) Use of scaffold comprising fibrin for delivery of stem cells
DE602006013191D1 (de) Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
TW200716091A (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
TNSN08277A1 (en) Materials and methods for treating chronic fibrotic disease
IL192181A0 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
WO2007087151A3 (en) Combination of ache inhibitor and 5-ht6 antagonist for the treatment of cognitive dysfunction
ATE435858T1 (de) Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen
MX2011012015A (es) Tratamiento de deterioro cognitivo leve y enfermedad de alzheimer.
HK1112721A1 (en) Tissue disruption treatment and composition for use thereof
RS54185B1 (en) USE OF 24-ORDER
WO2006128740A3 (en) Anti-vascular methods and therapies employing lysyl oxidase inhibitors